This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pillar, C. M.
Right arrow Articles by Sahm, D. F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2008, p. 2862-2867, Vol. 46, No. 9
0095-1137/08/$08.00+0     doi:10.1128/JCM.00637-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of Tigecycline against Gram-Positive and Gram-Negative Pathogens as Evaluated by Broth Microdilution and Etest{triangledown}

Chris M. Pillar,1* Deborah C. Draghi,1 Michael J. Dowzicky,2 and Daniel F. Sahm1

Eurofins Medinet, Inc., Herndon, Virginia,1 Wyeth Pharmaceuticals, Collegeville, Pennsylvania2

Received 3 April 2008/ Returned for modification 6 May 2008/ Accepted 22 June 2008

The current surveillance establishes the activity profile of tigecycline against recent clinical U.S. isolates of target pathogens. Findings from a distributed surveillance that utilized Etest yielded a tigecycline activity profile that varied from that observed in a separate centralized broth microdilution (BMD) surveillance (D. C. Draghi et al., Poster D-0701, 46th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA). Differences were noted among Acinetobacter spp. and Serratia marcescens and, to a lesser extent, with Streptococcus pyogenes. To address whether these differences were due to discordance in testing methodology or to variations among the analyzed populations, isolates from the current surveillance were concurrently tested by BMD and Etest. In all, 1,800 Staphylococcus aureus, 259 S. pyogenes, 226 Streptococcus pneumoniae, 93 Enterococcus faecalis, 1,356 Enterobacteriaceae, and 227 Acinetobacter baumannii strains were evaluated. Tigecycline had potent activity by BMD, with >99.6% susceptibility (%S) observed for all pathogens with interpretive criteria, excluding Enterobacter cloacae (98.3% S) and E. faecalis (86.0% S), and MIC90s ranged from 0.03 µg/ml (S. pyogenes/S. pneumoniae) to 1 µg/ml (Enterobacteriaceae/A. baumannii). Similar profiles were observed by Etest, with the exception of A. baumannii, although for most evaluated pathogens Etest MICs trended one doubling-dilution higher than BMD MICs. Major or very major errors were infrequent, and a high degree of essential agreement was observed, excluding A. baumannii, S. marcescens, and S. pneumoniae, for which ≥4-fold differences in MICs were observed for 29, 27.1, and 34% of the isolates, respectively. Further analysis regarding the suitability of the tigecycline Etest for testing S. marcescens, Acinetobacter spp., and S. pneumoniae is warranted.

* Corresponding author. Mailing address: Eurofins Medinet, 13665 Dulles Technology Drive, Suite 200, Herndon, VA 20171. Phone: (703) 480-2535. Fax: (703) 480-2654. E-mail: chris.pillar{at}eurofinsmedinet.com

{triangledown} Published ahead of print on 2 July 2008.

Journal of Clinical Microbiology, September 2008, p. 2862-2867, Vol. 46, No. 9
0095-1137/08/$08.00+0     doi:10.1128/JCM.00637-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Casal, M., Rodriguez, F., Johnson, B., Garduno, E., Tubau, F., de Lejarazu, R. O., Tenorio, A., Gimenez, M. J., Bartolome, R., Garcia-Rey, C., Aguilar, L., Garcia-Escribano, N. (2009). Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp.. J Antimicrob Chemother 64: 69-72 [Abstract] [Full Text]  
  • Gallagher, J. C, Rouse, H. M (2008). Authors' Reply. The Annals of Pharmacotherapy 42: 1718-1718 [Full Text]  
  • Curcio, D. (2008). Comment: Tigecycline for the Treatment of Acinetobacter Infections: A Case Series. The Annals of Pharmacotherapy 42: 1717-1718 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»